Development and testing of a utility measure for major, unipolar depression (McSad)
- PMID: 10981211
- DOI: 10.1023/a:1008952602494
Development and testing of a utility measure for major, unipolar depression (McSad)
Abstract
Objective: To develop and test a direct utility measure (McSad) for major, unipolar depression.
Methods: A depression specific, multi-attribute health state classification system was created; clinical validity was evaluated by experts using specially designed structured exercises; a cross-sectional survey was conducted to obtain directly measured utilities for depression health states.
Setting: Tertiary care, university medical centre.
Participants: Three psychiatrists, 3 psychiatric nurses and 3 social workers assessed depression health state clinical validity. Survey participants were referred by psychiatrists and consisted of 105 outpatients, currently in remission with at least one episode of major, unipolar depression in the past two years.
Survey results: Respondent self-health state utility (mean and 95% confidence interval (CI)) was 0.79 (0.74-0.83). Utilities for hypothetical, untreated depression health states were: mild depression, 0.59 (0.55-0.62); moderate depression, 0.32 (0.29-0.34); severe depression, 0.04 (0.01-0.07). Fifty-six percent of respondents rated severe depression worse than being dead. Utilities for the hypothetical health states were not correlated with self-health utility. The intra-class correlation coefficient (ICC) was satisfactory for 13 of the 14 health states assessed.
Conclusions: McSad was feasible and acceptable in patients with a history of major unipolar depression. The utilities for mild, moderate and severe untreated depression show the low health-related quality of life associated with depression. Initial assessments of test-retest reliability and validity yielded satisfactory results but further studies are needed to extend our knowledge of the measurement properties of McSad.
Similar articles
-
Testing the McSad depression specific classification system in patients with somatic conditions: validity and performance.Health Qual Life Outcomes. 2013 Jul 26;11:125. doi: 10.1186/1477-7525-11-125. Health Qual Life Outcomes. 2013. PMID: 23886474 Free PMC article.
-
Cost-utility analysis in depression: the McSad utility measure for depression health states.Psychiatr Serv. 2000 Sep;51(9):1171-6. doi: 10.1176/appi.ps.51.9.1171. Psychiatr Serv. 2000. PMID: 10970923
-
Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life.J Clin Psychiatry. 2006 Oct;67(10):1536-41. doi: 10.4088/jcp.v67n1007. J Clin Psychiatry. 2006. PMID: 17107244
-
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications.J Affect Disord. 1998 Feb;48(1):25-36. doi: 10.1016/s0165-0327(97)00117-1. J Affect Disord. 1998. PMID: 9495599
-
Utility scores for different health states related to depression: individual participant data analysis.Qual Life Res. 2017 Jul;26(7):1649-1658. doi: 10.1007/s11136-017-1536-2. Epub 2017 Mar 4. Qual Life Res. 2017. PMID: 28260149 Free PMC article. Review.
Cited by
-
Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients.Qual Life Res. 2007 Dec;16(10):1665-75. doi: 10.1007/s11136-007-9264-7. Epub 2007 Oct 3. Qual Life Res. 2007. PMID: 17912614
-
Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder.Health Qual Life Outcomes. 2004 May 5;2:20. doi: 10.1186/1477-7525-2-20. Health Qual Life Outcomes. 2004. PMID: 15128456 Free PMC article.
-
Valuation of depression co-occurring with a somatic condition: feasibility of the time trade-off task.Health Expect. 2015 Dec;18(6):3147-59. doi: 10.1111/hex.12303. Epub 2014 Nov 13. Health Expect. 2015. PMID: 25393599 Free PMC article.
-
When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.Neuropsychopharmacology. 2009 Sep;34(10):2227-36. doi: 10.1038/npp.2009.50. Epub 2009 Jun 3. Neuropsychopharmacology. 2009. PMID: 19494805 Free PMC article.
-
The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale.Pharmacoeconomics. 2007;25(7):591-603. doi: 10.2165/00019053-200725070-00005. Pharmacoeconomics. 2007. PMID: 17610339
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous